Samuel Waxman is a partner in the Emerging Growth Company and Corporate practices at Paul Hastings. He is based in the firm’s New York office.
Mr. Waxman represents emerging to mature life sciences and technology companies is all aspects of their business and legal affairs, including company formation, equity financings, strategic alliances, IPOs and M&A transactions. Mr. Waxman also regularly represents venture capital and growth equity investment funds.
- Recognized as a leading M&A, technology and intellectual property lawyer in the Financial Times Innovative Lawyers Report, The Legal 500 and Chambers.
- Intellectual Asset Management’s Patent 1000: The World’s Leading Patent Practitioners stated, "The ‘street-smart’ lawyer has made the most of an outstanding transactional platform at the firm and proved his mettle on some of the biggest acquisitions/divestitures around."
- Named to the top "40 Under 40 M&A Professionals" in M&A Advisor (2012)
- University of Virginia School of Law, J.D., 2000
- University of Virginia, B.A. (with Distinction), 1997
Strategic Alliances and M&A
- Deerfield Management, in connection with its five-year partnership with Illumina, Inc. to apply a gene-based approach to the discovery and development of new treatments for diseases with unmet medical needs.
- Deerfield Management, in connection with its early-stage therapeutic research partnerships with various elite academic institutions including The Broad Institute of MIT and Harvard, Johns Hopkins University, Harvard University, and the Dana Farber Cancer Institute.
- Merck & Co. in connection with various M&A and strategic alliance transactions, most recently in connection with its strategic alliances with Amathus Therapeutics and Yumanity Therapeutics.
- Elanco U.S., Inc., a subsidiary of Eli Lilly and Company, in its acquisition of Boehringer Ingelheim Vetmedica’s U.S. feline, canine and rabies vaccines portfolio.
- Sony Corporation in connection with various M&A transactions.
Venture Capital & Emerging Growth Companies
- Deerfield Management, in connection with various debt and minority equity investments.
- Apertura Gene Therapy, in its $67 million Series A financing and its foundational in-licenses from The Broad Institute of MIT and Harvard and Harvard Medical School.
- Loadsmart, a leading freight technology company, in its $200 million Series D financing.
- Neomorph, Inc., in its $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs.
- Jaguar Gene Therapy, LLC in connection with its $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management.
- Axovia Therapeutics, Inc., an gene therapy company developing disease-transformative medicines for ciliopathies, in connection with its Series A financing.
- Orchestra BioMed, Inc., a biomedical innovation company, in connection with its $72 million Series B/B1 financings.
- Clearview AI, a leading facial recognition company, in connection with its $30 million Series B financing.
- Flex, a NYC-based FinTech company, in connection with its equity financings.
- Digitalis Ventures, as outside general counsel.
- Canopy Growth Corporation, in connection with various M&A transactions, including its agreement to acquire Acreage Holdings and Wana Brands.
- Cresco Labs, in connection with various M&A transactions, including its announced acquisition of Columbia Care.
- The Scotts Miracle-Gro Company, in connection with its acquisition of Luxx Lighting, and its minority investment in RIV Capital.
- RIV Capital, in connection with various investment transactions, including its announced acquisition of Etain.
- Turning Point Brands, in connection with various debt and minority equity investments.
- Tuatara Capital, in connection with various debt and minority equity investments.
Engagement & Publications
- Moderator, "Early-Stage Company Pitfalls and Risk Considerations", the Cure Symposia by Deerfield, November 2021
- Moderator, "Beyond the Science: What Principal Investigators (PIs) Need to Consider When Negotiating", the Cure Symposia by Deerfield, October 2021
- Moderator, "The Future of Venture Capital", New York Venture Summit, July 2018
- Smarter, Faster, Stronger: A New Suite of VC Model Docs, Law360, May 2018
- NYC: Municipal Benefactor to Life Sciences and Technology Venture Capital, Lexology, Nov 2017
- Plenary Session Moderator, "In Pursuit of Growth, Savings, and Return on Investment: Pharma’s Quest for Innovation Partnerships", Life Sciences Summit, November 2017
- Guest Lecturer, "Life Sciences Patent Law", NYU School of Law, April 2017
- Resigning From a Board of Directors: Considerations for VC Fund Designees, Lexology, March 2017
- Panelist, Houlihan Lokey 2017 Illiquid Financial Assets Conference, March 2017
- Venture Debt: An Attractive Tool for Start-up Companies, Law360, February 2017
- Making the Grade: Negotiating IP Licenses with Academic Institutions, Licensing Journal, January 2017, Vol. 37 Issue 1
- Panelist, "Dealmaking 2017: Exploring Academic-Industry Partnerships", New York Pharma Forum, January 2017
- Revisiting the CVR: The Litigation Crucible, Lexology, November 2016
- When Minority Stockholders Take Control: Recent Delaware Cases Shine a Light on Fiduciary Obligations of Controlling Shareholders, Law360, July 2016
- Legal Health Isn't Easy for Digital Health Companies, TechCrunch. April 2016.
- Post-Closing Fraud Claims in the Acquisition Context: Protecting the Seller, Lexology, February 2016
- Solving The Valuation Puzzle in Life Sciences Transactions: The Pros and Cons of the CVR, The M&A Lawyer, January 2016.
- Not Just Refrigerators and Light Bulbs: Connected Vehicles as an Extension of the Internet of Things, Lexology, April 2015.
- The Acquisition of IP Assets in Bankruptcy, Intellectual Property Magazine, July/August 2014.